SEC Filing Summary: ReShape Lifesciences Inc. (RSLS)
Business Context and Reporting Period
This Form 8-K was filed by ReShape Lifesciences Inc. (RSLS) on July 15, 2022. The registrant is a Delaware corporation with its principal executive offices in San Clemente, CA. The company's common stock trades on The Nasdaq Capital Market under the symbol RSLS. The filing reports a corporate governance event regarding the appointment of a new independent registered public accounting firm.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a change in the registrant's certifying accountant and does not contain financial performance data.
Material Changes
On July 15, 2022, the Audit Committee of the Board of Directors appointed RSM US LLP as the Company's independent registered public accounting firm. The filing states that during the fiscal years ended December 31, 2021 and 2020, and subsequent interim periods, the Company did not consult with RSM regarding accounting principles, audit opinions, disagreements with former auditors, or reportable events.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies are detailed beyond the standard disclosure regarding the transition of the audit firm.
Key Facts for Investor Verification
- New Auditor: RSM US LLP was appointed as the independent registered public accounting firm effective July 15, 2022.
- No Prior Consultation: The Company confirmed no consultations occurred with RSM regarding accounting principles or disagreements with former auditors prior to this appointment.
- Emerging Growth Company: The registrant is identified as an emerging growth company.
- Missing Financials: This 8-K does not contain financial results; investors should refer to the most recent 10-K or 10-Q for financial metrics.